Physician profile
Keith M Tobin
NPI 1083611560
$6,747.01
in general payments reported to CMS, 2019-2025
41 companies · $1,293 in 2025
The $1,293 reported for 2025 was more than what 93% of Geriatric Medicine (Family Medicine) providers received nationally (typical 2025 total: $119).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,329 · 2020: $662 · 2021: $928 · 2022: $660 · 2023: $937 · 2024: $939 · 2025: $1,293.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,168.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,168.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $846.65 | 2019-2025 | Vraylar, Qulipta |
| Glaxosmithkline, LLC. | $737.92 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals Lp | $635.34 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $476.70 | 2019-2025 | Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $471.92 | 2023-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $407.39 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $334.17 | 2019-2023 | Xarelto |
| Lilly USA, LLC | $311.83 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $283.51 | 2019-2024 | Repatha |
| Pfizer INC. | $222.57 | 2019-2025 | |
| Novo Nordisk INC | $193.42 | 2019-2025 | Ozempic, Rybelsus |
| Sanofi-Aventis U.S. LLC | $189.12 | 2019-2023 | |
| Eisai INC. | $144.63 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $135.79 | 2019-2025 | Capvaxive, Gardasil 9, Varivax |
| Horizon Therapeutics Plc | $131.10 | 2019 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Tobin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.